Key result
Prior aspirin administration significantly reduced early platelet deposition at angioplasty sites in men compared to no aspirin.
Why the study?
Does prior aspirin administration reduce platelet deposition at angioplasty sites in men undergoing transluminal angioplasty?
Observational (n=17)
Does prior aspirin administration reduce platelet deposition at angioplasty sites in men undergoing transluminal angioplasty?
Aspirin administration prior to peripheral angioplasty significantly limits early platelet deposition at the site of arterial injury.
May support aspirin pretreatment before angioplasty in men; leaves open clinical event reduction and requires randomized confirmation.
In-111 platelet scintigraphy was used to evaluate the effects of prior aspirin administration on the accumulation of In-111-labeled autologous platelets at sites of arterial injury resulting from iliac, femoral, or popliteal transluminal angioplasty in a nonrandomized study of 17 men. The degree of platelet localization at angioplasty sites was significantly less in nine men who had received aspirin in varying doses within the 4 days before angioplasty than in eight men who had not received aspirin for at least two weeks. Our results suggest that aspirin treatment before angioplasty limits the early platelet deposition at the angioplasty site in men.
No takes yet. Share an insight, caveat, or question.
Cunningham et al. (1984) conducted an observational in Arterial injury from transluminal angioplasty (n=17). Aspirin vs. No aspirin for at least two weeks was evaluated on Degree of platelet localization at angioplasty sites. Prior aspirin administration significantly reduced early platelet deposition at angioplasty sites in men compared to no aspirin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: